22OCT

UK startups raise $6.1bn in Q3, below Dealroom's pace

2 min read

16:30UTC

HSBC Innovation Banking's count on Dealroom data put the third quarter at $6.1bn, short of the run rate Dealroom projected in July.

← Back to Stryker agrees option to buy CMR Surgical Jump to analysis ↓

TechnologyDeveloping

Key takeaway

Q3 UK venture fell short of Dealroom's pace, and a few large rounds carried it.

UK startups raised $6.1bn in the third quarter, according to HSBC Innovation Banking's Q3 update on Dealroom data⁠¹. That is below the roughly $8.5bn a quarter implied by Dealroom's July projection of $34.2bn for the year. Crunchbase, counting on its own method, puts the quarter at $7.5bn⁠².

One name carries much of the $6.1bn. CityFibre, a broadband network builder, supplied about a fifth of the quarter with a $1.2bn growth round. Eleven rounds of $100m or more made up $3.5bn, or 58%. Health led on deal count with 62 rounds worth $645m. Semiconductor companies have raised a record $1.59bn in the first nine months of the year.

UK venture firms raised a record $6.9bn across 31 new funds in the quarter, and Index Ventures took about $3.5bn of it, just over half⁠³.

Startupmag's weekly tallies for 21 September to 16 October count 84 disclosed rounds worth about £4bn⁠⁴. Nscale's notes, CMR Surgical and OMass make up about three quarters of it. The rest comes to about £970m, roughly £240m a week on Startupmag's count, with a handful of rounds between £45m and about £106m above a long tail of smaller ones.

Deep Analysis

In plain English

Venture capital is money that investors put into young, fast-growing companies in return for a share of them. Several data firms count how much British startups raise, and each counts differently. One count, from Dealroom, says British startups raised $6.1bn between July and September. Another, from Crunchbase, says $7.5bn. Both sit below the pace Dealroom forecast in July. A single deal for CityFibre, which builds broadband networks, made up about a fifth of Dealroom's total.

Deep Analysis

Root Causes

Dealroom and Crunchbase classify rounds differently: they disagree on infrastructure companies, debt, secondary sales and the date a round is counted. Each method is internally consistent, which is why their totals cannot be added or averaged.

Large-round dependence also follows from the cost of AI and deep tech. Companies building data centres, chips or drugs raise in hundreds of millions, so a handful of rounds can set any quarter's total.

What could happen next?

Consequence
On HSBC Innovation Banking's Dealroom figures, the July projection for 2026 now needs an unusually large fourth quarter.
Meaning
Headline totals from different trackers cannot be compared with each other, only each with its own past figures.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: In December 2018 Altria paid $12.8bn for 35% of the e-cigarette maker Juul, and venture trackers split on whether to count it as a venture deal. Depending on the tracker, one cheque moved the American annual total by billions of dollars.

Counter-parallel: No clean case shows a quarter dominated by an infrastructure round that went on to predict a broad startup recovery. Mega-round quarters have tended to say more about one company than about the market.

Fund-raising tells a different story from deployment. AltAssets reported a record $6.9bn raised by UK venture firms across 31 funds, about $3.5bn of it by Index Ventures, so the fund-raising record is concentrated in one manager.

Index Ventures and other managers typically invest a new fund over three to five years. A record raising quarter therefore feeds future deployment, not this quarter's company rounds.

Consensus view: HSBC Innovation Banking, working from Dealroom data, shows the quarter resting on large rounds: eleven of $100m or more supplied $3.5bn of its $6.1bn. On that dataset the growth Dealroom projected in July needs a much stronger final quarter.

Counter-view: Crunchbase counts the same quarter at $7.5bn using its own rules on what qualifies as a startup round. The $1.4bn gap between the two trackers is larger than most single rounds, so the verdict on the quarter depends on which method a reader trusts.

Key tension: Whether CityFibre's $1.2bn growth round, a fibre network build, belongs in a startup venture total at all, since its removal would change the Dealroom quarter more than any trend.

Sources:Startupmag·HSBC Innovation Banking·Crunchbase News

Mentions:HSBC Innovation Banking →Dealroom →Crunchbase →CityFibre →Index Ventures →CMR Surgical →Nscale →HSBC →OMass Therapeutics →

First Reported In

Update #16 · Stryker agrees option to buy CMR Surgical

Startupmag· 22 Oct 2026

Read original →

Causes and effects

Caused by

Dealroom projects $34.2bn for UK tech

Third-quarter funding came in below the quarterly pace Dealroom's $34.2bn projection implied.

Occurred 23 Jul 2026

Read story →

This Event

UK startups raise $6.1bn in Q3, below Dealroom's pace

A handful of very large rounds carried the quarter, and the market beneath them is much thinner than the headline total.

Different Perspectives

Abu Dhabi Investment Council

The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.

CDP Venture Capital

CDP Venture Capital, the venture arm of Italy's state lender, led TrueLayer's £20.4m round to expand Pay by Bank across Europe. A foreign state investor set the terms on a London fintech round in the same month the British Business Bank mostly followed.

EDBI

Singapore's state investor EDBI joined Universal Quantum's Series A of more than $100m, and the Sussex company is opening its first research centre outside Europe in Singapore. British state money is absent from the largest Series A by a UK quantum company.

Forbion

Forbion co-led OMass Therapeutics' $310m Series C with Bain Capital Life Sciences and Novo Holdings, while the British Business Bank and Syncona followed. The terms of the Oxford spinout's round were set by investors from three countries, none of them Britain.

British Business Bank

The Bank committed £180m to six AI funds on 15 October with no UK-deployment condition, yet led the first close of Microbiotica's £36m Series C. That lead, with Airtel Money choosing London for its £5.3bn debut, is the evidence that British money and markets still set some terms.

Stryker Corporation

Stryker called its roughly $400m CMR Surgical deal its entry into soft-tissue robotics, taking US sales rights for Versius, a board seat and an exclusive option over 100% of the company. The option lets Stryker choose whether and when a Cambridge robot maker becomes part of an American group.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.